How to Get Trulicity in Colorado: Prescriptions, Telehealth, and Pharmacy Guide

What Is Trulicity and Why Colorado Patients Seek It

Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for glycemic control in adults with type 2 diabetes and, separately, for reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple risk factors. Colorado has seen rising demand for GLP-1 therapies alongside national trends driven by published outcomes data.

The drug works by stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. The net effect is lower postprandial glucose, modest fasting glucose reduction, and a 1.4 to 1.6 percentage-point average HbA1c drop at the 1.5 mg maintenance dose in the AWARD-5 trial (N=1,098), which compared dulaglutide to sitagliptin over 104 weeks [1]. That same trial showed a statistically significant advantage for dulaglutide at week 52 (HbA1c reduction: 1.1% dulaglutide 1.5 mg vs. 0.6% sitagliptin, P<0.001) [1].

For cardiovascular outcomes, the REWIND trial (N=9,901, median follow-up 5.4 years, published in The Lancet 2019) showed dulaglutide 1.5 mg once weekly reduced the composite of nonfatal MI, nonfatal stroke, or CV death by 12% relative to placebo (HR 0.88 to 95% CI 0.79, 0.99, P=0.026) [2]. Colorado providers who treat patients with type 2 diabetes and elevated cardiovascular risk cite REWIND frequently when selecting GLP-1 therapy.

The FDA label for Trulicity specifies contraindications including a personal or family history of medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia syndrome type 2 (MEN 2) [3]. Providers in Colorado are required to document this screening at the prescribing visit.

Who Can Prescribe Trulicity in Colorado

Any Colorado-licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) may prescribe dulaglutide. Colorado grants NPs full practice authority under Colorado Revised Statutes 12-255-112, meaning NPs may prescribe Schedule II through V controlled substances and standard prescription drugs, including GLP-1 agonists, without a physician collaboration agreement [4]. PAs in Colorado operate under a practice agreement with a supervising or collaborating physician but retain broad prescriptive authority for non-controlled medications.

This matters practically. Telehealth platforms staffed by NPs can issue a dulaglutide prescription to a Colorado patient without any in-state physician co-signature, which shortens the path from initial visit to prescription by one to three business days compared with states requiring physician oversight.

Prescribers must hold an active Colorado license in their profession and comply with Colorado's telehealth prescribing statute (C.R.S. 10-16-123), which requires that the prescriber establish a valid patient-provider relationship before issuing a prescription [5]. A synchronous video visit satisfies this requirement; asynchronous (store-and-forward) encounters alone generally do not for a new Schedule V or standard Rx in Colorado.

Labs and Clinical Evaluation Required Before Prescribing

A complete pre-prescribing workup reduces adverse events and supports prior authorization approvals. Colorado providers typically order the following panel before initiating dulaglutide.

Baseline labs most Colorado prescribers order:

• Hemoglobin A1c (HbA1c): confirms diagnosis of type 2 diabetes (threshold: 6.5% per ADA 2024 Standards of Care) [6]
• Fasting plasma glucose or 2-hour OGTT if HbA1c is borderline
• Comprehensive metabolic panel (CMP): kidney function (eGFR, creatinine) and liver enzymes
• Lipid panel: baseline cardiovascular risk stratification
• TSH: thyroid function screen; MTC risk is contraindication per FDA label [3]
• Urine albumin-to-creatinine ratio (UACR): baseline renal marker, relevant for dosing conversations
• Body weight and BMI: dulaglutide is indicated for T2D regardless of BMI <27 or above

The ADA's 2024 Standards of Medical Care in Diabetes recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred agents in patients with type 2 diabetes and established ASCVD, heart failure, or chronic kidney disease, irrespective of baseline HbA1c [6]. Colorado endocrinologists and primary care physicians follow this guidance closely, and insurers sometimes require documentation that the ADA algorithm was applied when processing prior authorization.

Patients with a history of pancreatitis require individual risk-benefit discussion. The FDA label notes postmarketing reports of acute pancreatitis with dulaglutide [3], and the prescriber should document the conversation in the chart.

How to Get a Trulicity Prescription in Colorado: Step-by-Step

Getting dulaglutide prescribed in Colorado follows a straightforward sequence whether you use a telehealth service or see a clinician in person.

Step 1. Schedule a visit. Book an appointment with a Colorado-licensed MD, DO, NP, or PA. Telehealth platforms licensed in Colorado can see new patients via synchronous video. Most schedules have availability within two to five business days.

Step 2. Complete intake forms. Provide current medication list, allergy history, prior diabetes medications tried, and relevant family history (especially thyroid cancer, MEN 2, or pancreatitis).

Step 3. Order labs. The provider orders the baseline panel described above. Most Colorado labs (Quest, LabCorp, UCHealth outpatient labs) return results in one to two business days. Telehealth providers typically send an electronic lab order to a location near the patient.

Step 4. Review results at a follow-up visit or asynchronously. Once labs confirm eligibility (HbA1c 6.5% or above, no contraindications), the prescriber sends the dulaglutide Rx electronically to the patient's chosen pharmacy.

Step 5. Pharmacy dispensing or insurance submission. If using insurance, the pharmacy submits a claim. If prior authorization is required (see section below), the prescriber's office handles paperwork. Cash-pay patients at retail or 503A pharmacies skip the PA process.

Step 6. Injection training. The pre-filled Trulicity pen is designed for self-administration. Most Colorado telehealth providers provide a video demonstration link or PDF guide. The FDA-approved patient instructions are embedded in the Trulicity package insert [3].

Telehealth Prescribing in Colorado for Trulicity

Colorado explicitly permits telehealth prescribing of non-controlled medications including dulaglutide. The Colorado Division of Insurance rule 10-16-123 requires insurers that cover in-person services to cover equivalent telehealth services, and the prescribing rules for telehealth providers mirror those for in-person clinicians [5].

A Colorado-licensed telehealth provider may prescribe Trulicity after a synchronous video visit that establishes a clinical relationship. The prescription is then sent electronically to a pharmacy of the patient's choice, including mail-order pharmacies licensed in Colorado or local retail chains.

The Colorado Medical Board has not issued any moratorium or special restriction on GLP-1 prescribing via telehealth. The main practical limitation is that the prescriber must be licensed in Colorado, not merely in an adjacent state, unless operating under an interstate compact. Colorado participates in the Interstate Medical Licensure Compact (IMLC) for physicians [7] and the Nurse Licensure Compact (NLC) for RNs, though NP prescriptive authority compacts are state-specific.

Patients using telehealth platforms should verify that the platform's prescribing clinician holds an active Colorado license. The Colorado Department of Regulatory Agencies (DORA) license lookup tool confirms licensure status in under two minutes [8].

Prior Authorization: What Colorado Insurers Require

Prior authorization (PA) is the single largest administrative barrier to Trulicity access in Colorado. Most commercial plans in Colorado, including Anthem, Cigna, Aetna, and UnitedHealthcare of Colorado, require PA before dispensing dulaglutide.

Standard PA documentation requirements in Colorado typically include:

• Confirmed diagnosis of type 2 diabetes (ICD-10: E11.x) with HbA1c at or above 7.0% (some plans: 7.5% or 8.0%)
• Documented trial of at least one first-line agent (metformin is the most common requirement, often 90 days minimum)
• A formulary step through a lower-tier GLP-1 if the plan places dulaglutide on tier 3 or higher
• Prescriber attestation that a GLP-1 with CV benefit is clinically indicated per ADA 2024 guidelines [6]
• Recent HbA1c lab result (usually within 90 days)
• For CV indication: documentation of prior ASCVD event or established multiple risk factors

Colorado law (C.R.S. 10-16-113.5) requires commercial insurers to process standard PA requests within three business days and urgent requests within 24 hours [9]. If a PA is denied, Colorado law grants appeal rights including external independent review.

Colorado Medicaid (Health First Colorado) does not currently cover Trulicity for the type 2 diabetes indication. Patients on Medicaid should ask their provider about ozempic (semaglutide) or other GLP-1 agents that appear on the Health First Colorado preferred drug list, as coverage varies by specific agent and indication.

Trulicity Pharmacy Options in Colorado

Once a prescription is issued, Colorado patients have several dispensing routes.

Retail chains. Walgreens, King Soopers (Kroger), CVS, and Walmart pharmacies across Colorado stock Trulicity or can order it within one to two business days. The cash price for a four-pen (four-week) carton of Trulicity 1.5 mg runs approximately $900 to $1,000 without insurance as of mid-2025, though GoodRx and manufacturer coupons reduce this significantly.

Lilly Cares Foundation. Eli Lilly offers an insulin and diabetes medication assistance program. Patients with household income at or below 400% of the federal poverty level may qualify for Trulicity at no cost through Lilly's patient assistance program [10].

Lilly's $35 insulin/diabetes savings card. For insured patients, Lilly's savings card may reduce the co-pay to $35 per month for eligible commercial insurance holders [10].

Mail-order pharmacies. Colorado Blue Cross Blue Shield, Cigna, and most large commercial plans allow or require 90-day mail-order fills for maintenance medications. Mail-order often reduces per-unit cost by 20 to 30%.

503A compounding pharmacies. Colorado-licensed 503A compounding pharmacies may prepare patient-specific compounded formulations of dulaglutide. A 503A pharmacy compounds for an individual patient pursuant to a valid prescription and is regulated by the Colorado State Board of Pharmacy under C.R.S. 12-280-125 [11]. Compounded dulaglutide is chemically equivalent in active moiety but is not FDA-approved and does not carry the Trulicity brand's safety data package. Patients should verify the pharmacy's state license via the Colorado DORA pharmacy lookup [8].

The FDA distinguishes 503A (patient-specific compounding pharmacies) from 503B (outsourcing facilities). Colorado has several registered 503A pharmacies authorized to compound peptides and GLP-1 analogs when a brand shortage or clinical necessity is documented [12].

Dosing Schedule for Dulaglutide

Trulicity is initiated at 0.75 mg subcutaneously once weekly. After four weeks at 0.75 mg, the provider may increase to 1.5 mg once weekly, the most commonly studied maintenance dose in REWIND [2] and AWARD trials [1]. For patients needing additional glycemic control, the FDA approved a 3.0 mg and 4.5 mg dose in 2020, supported by the AWARD-11 trial (N=1,842), which showed HbA1c reductions of 1.6% (3.0 mg) and 1.6% (4.5 mg) versus 1.3% at 1.5 mg at 36 weeks [13].

The injection can be given on any day of the week and at any time of day, with or without food. The injection site may rotate among the abdomen, thigh, or upper arm. No dose adjustment is required for mild or moderate renal impairment; data in severe renal impairment (eGFR <15 mL/min/1.73 m²) are limited per the FDA label [3].

Transferring an Existing Trulicity Prescription to Colorado

Patients relocating to Colorado with an active dulaglutide prescription from another state can transfer fills to a Colorado pharmacy provided:

1. The prescription was issued by a provider licensed in the originating state and is still valid (most states allow up to 12 months from issue date for non-controlled Rx).
2. The prescribing provider is willing to continue care or the patient establishes care with a Colorado-licensed provider.
3. The receiving Colorado pharmacy accepts transfers (all major retail chains do for non-controlled medications).

If the patient's original prescriber is not licensed in Colorado and the patient has no Colorado provider, a telehealth visit with a Colorado-licensed clinician to reissue the prescription takes one to three business days. Telehealth providers typically require the patient's most recent HbA1c (within six months) to reissue without repeating a full workup.

Colorado does not have a reciprocal prescribing agreement with other states; the prescribing clinician must hold a Colorado license or be practicing under IMLC [7].

Managing Side Effects in Colorado: Clinical Resources

The most common adverse effects of dulaglutide are gastrointestinal: nausea (12.4% to 21.1%), diarrhea (8.9% to 12.6%), vomiting (5.8% to 12.0%), and decreased appetite, per pooled AWARD trial data reviewed in the FDA label [3]. These effects typically peak in the first four weeks and diminish with time.

Colorado patients experiencing severe or persistent GI symptoms should contact their prescribing provider. Telehealth platforms generally offer asynchronous messaging within 24 hours for side effect management. Dose reduction from 1.5 mg back to 0.75 mg is supported by the FDA label as a temporary measure [3].

The Colorado Poison Center (1-800-222-1222) handles overdose inquiries 24 hours a day. Accidental injection of a double dose is unlikely to cause hypoglycemia as a monotherapy but should be reported to a provider.

The American Diabetes Association's clinical practice guidelines note that GLP-1 receptor agonists used as monotherapy carry low intrinsic hypoglycemia risk because insulin secretion is glucose-dependent [6]. This distinguishes dulaglutide from sulfonylureas, where hypoglycemia is a meaningful concern.

Cost Assistance and Insurance Appeals in Colorado

Sticker price without insurance is high. Patients should exhaust these options in order:

Manufacturer savings card. Lilly's savings program for commercially insured patients can reduce monthly out-of-pocket cost. Eligibility and current terms are posted on the Lilly Cares site [10].

GoodRx / Mark Cuban Cost Plus Drugs. GoodRx coupons at Colorado retail pharmacies typically place the four-pen carton in the $700 to $850 range. Cost Plus Drugs (costplusdrugs.com) does not currently list Trulicity but lists competing GLP-1 agents at lower margins.

Insurance appeals. Under Colorado law (C.R.S. 10-16-113.5), a denied PA can be appealed internally within 30 days, and an external independent review can be requested if the internal appeal fails [9]. The Colorado Division of Insurance (doi.colorado.gov) provides a consumer complaint process if an insurer violates the 3-business-day PA review requirement.

Patient assistance programs. Uninsured patients earning at or below 400% of the federal poverty level may apply to the Lilly Cares Foundation, which can provide Trulicity at no cost [10].

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on GLP-1 access states: "Prior authorization requirements that mandate failure of multiple agents before approving a GLP-1 with proven cardiovascular benefit in a high-risk patient create clinically unjustifiable delays in care." [14] Colorado providers can cite this language in PA appeal letters.

How Long Until You Receive Trulicity in Colorado

From initial telehealth visit to pen-in-hand, timelines vary by path:

• Cash pay, retail pharmacy (no PA): 2 to 5 business days (1 day for telehealth visit, 1 to 2 days for labs, 1 day for prescription transmission, 0 to 2 days for dispensing).
• Insurance with PA, approval: 7 to 14 business days on average when the PA is approved on first submission.
• Insurance with PA, appeal: 30 to 60 days if an internal or external appeal is required.
• 503A compounding pharmacy: 5 to 10 business days after prescription receipt, depending on the pharmacy's compounding queue.

Patients with urgent clinical need (HbA1c above 10%, symptomatic hyperglycemia) may request expedited PA review under the 24-hour urgent pathway specified in Colorado law [9].